Predicting therapeutic responses in head and neck squamous cell carcinoma from < em > TP53 < /em > mutation detected by cell-free DNA
CONCLUSIONS: TP53 mutation could be used as a specific predictor of treatment response in patients with HNSCC. Using cfDNA to detect the TP53 mutations in patients with HSNCC is a feasible method. The results suggested that the therapeutic response in patients could be predicted by detecting TP53 mutations in cfDNA, and large-scale and prospective studies are needed to validate this hypothesis.PMID:38197078 | PMC:PMC10774070 | DOI:10.21037/tcr-23-878
Source: Cell Research - Category: Cytology Authors: Mei Wei Jingtai Zhi Li Li Wei Wang Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Cytology | Databases & Libraries | Epithelial Cancer | Genetics | Head and Neck Cancer | HNSCC | Hypopharyngeal Cancer | Immunotherapy | Laryngeal Cancer | Nasal Cavity and Paranasal Sinus Cancer | Nasopharyngeal Cancer | Oral Cancer | Oral Cavity Cancer | Oropharyngeal Cancer | Skin Cancer | Squamous Cell Carcinoma | Study